veldoreotide (DG3173) / Xeris Biopharma - LARVOL DELTA

Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches. (PubMed, Drugs) - "Medical therapies in current use for acromegaly are somatostatin receptor ligands (SRLs) (octreotide long-acting release [LAR], octreotide acetate, lanreotide depot, octreotide subcutaneous (SC) depot, pasireotide LAR, oral octreotide, paltusotine), dopamine agonists (cabergoline) and growth hormone receptor antagonists (pegvisomant)...Several investigational drugs are in development towards addressing unmet needs of patients with acromegaly, including new formulations of SRLs (lanreotide prolonged-release formulation, Debio 4126, pasireotide SC depot), novel SRLs (somatoprim, HTL0030310), monoclonal antibodies against growth hormone, and new growth hormone receptor antagonists. Current and emerging therapies are offering renewed hope for disease control. More studies including comparator agents, identification of accurate biomarkers and models predictive of clinical effectiveness may further improve the care of patients with acromegaly."

Journal • Review • Acromegaly • Endocrine Disorders • SSTR

Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. (PubMed, Life (Basel)) - "In the BON-1 cells expressing SSTR4, veldoreotide inhibited cell proliferation more than somatostatin SS-14 (71.2% vs. 79.7%) and to a similar extent as the SSTR4 agonist J-2156 in the presence of SSTR2 and SSTR5 antagonists. Veldoreotide is a full agonist of SSTR2, SSTR4, and SSTR5."

Journal • Pain • SSTR • SSTR2 • SSTR5

[VIRTUAL] Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide (ENDO-I 2020) - "In contrast, veldoreotide can activate both SST2 and SST5 receptors under otherwise identical conditions. Thus, veldoreotide is a unique SSA with full agonistic activity at the SST2, SST4, and SST5 receptors."

Neuroendocrine Tumor • Oncology • Solid Tumor • CGA, CHGA

Decarboxylative Peptide Macrocyclization through Photoredox Catalysis. (PubMed, Angew Chem Int Ed Engl) - "Linear precursors ranging from 3 to 15 amino acids cyclize effectively under this photoredox method. To demonstrate the preparative utility of this method in the context of bioactive molecules, we synthesized COR-005, a somatostatin analogue that is currently in clinical trials."

Journal • Biosimilar

Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide (ENDO 2020) - "In contrast, veldoreotide can activate both SST2 and SST5 receptors under otherwise identical conditions. Thus, veldoreotide is a unique SSA with full agonistic activity at the SST2, SST4, and SST5 receptors."

CGA, CHGA